KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$215.3 million.

  • Biogen's Change in Accured Expenses fell 12783.07% to -$215.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$248.0 million, marking a year-over-year decrease of 3878.01%. This contributed to the annual value of -$248.0 million for FY2025, which is 3878.01% down from last year.
  • Per Biogen's latest filing, its Change in Accured Expenses stood at -$215.3 million for Q4 2025, which was down 12783.07% from $286.0 million recorded in Q3 2025.
  • Over the past 5 years, Biogen's Change in Accured Expenses peaked at $1.1 billion during Q2 2022, and registered a low of -$745.7 million during Q4 2022.
  • Over the past 5 years, Biogen's median Change in Accured Expenses value was -$36.6 million (recorded in 2021), while the average stood at -$44.3 million.
  • Per our database at Business Quant, Biogen's Change in Accured Expenses plummeted by 85475.71% in 2022 and then skyrocketed by 2486470.59% in 2023.
  • Over the past 5 years, Biogen's Change in Accured Expenses (Quarter) stood at $98.8 million in 2021, then tumbled by 854.76% to -$745.7 million in 2022, then soared by 33.55% to -$495.5 million in 2023, then surged by 80.93% to -$94.5 million in 2024, then tumbled by 127.83% to -$215.3 million in 2025.
  • Its last three reported values are -$215.3 million in Q4 2025, $286.0 million for Q3 2025, and -$18.2 million during Q2 2025.